Janssen’s nipocalimab shows potential benefit in Phase 2 UNITY trial
The proof-of-concept trial showed that 54% of participants treated with nipocalimab met the primary endpoint of live birth…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 Jun 23
The proof-of-concept trial showed that 54% of participants treated with nipocalimab met the primary endpoint of live birth…
27 Jun 23
Study did not meet the primary endpoint
27 Jun 23
The first-in-class C5 inhibitor reduced disease severity and symptoms with sustained improvements over 26 weeks in Phase III…
26 Jun 23
The partnership intends to generate new data endpoints via a patient-centric and unobtrusive monitoring approach with a focus…
26 Jun 23
Embracing the "green pharma" philosophy, Lysando's Artilysin molecules effectively target resistant pathogens while minimizing environmental, wastewater, and food…
23 Jun 23
The merged firm will concentrate on developing Tourmaline's TOUR006 programme, an anti-IL-6 antibody to treat thyroid eye disease…
23 Jun 23
Lunaphore’s spatial biology portfolio uses precision microfluidic technology to find hyperplex proteomic and transcriptomic biomarkers in tumours and…
23 Jun 23
UPM Biomedicals’ innovative wound dressing FibDex is undergoing a clinical investigation of performance and safety in patients with…
23 Jun 23
The Sponsored Research Agreement will help advance antidepressant treatments for patients in need
22 Jun 23
AstraZeneca has discontinued and ceased dosing in the ongoing clinical studies of IL-4 receptor based on the lung…